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Abstract — This paper investigates the impact of fast 
parameter identification methods, which do not require any 
forward simulations, on model-based glucose control, using 
retrospective data in the Christchurch Hospital Intensive Care 
Unit. The integral-based identification method has been 
previously clinically validated and extensively applied in a 
number of biomedical applications; and is a crucial element in 
the presented model-based therapeutics approach. Common 
non-linear regression and gradient descent approaches are too 
computationally intense and not suitable for the glucose 
control applications presented. The main focus in this paper is 
on better characterizing and understanding the importance of 
the integral in the formulation and the effect it has on model-
based drug therapy control. As a comparison, a potentially 
more natural derivative formulation which has the same 
computation speed advantages is investigated, and is shown to 
go unstable with respect to modelling error which is always 
present clinically. The integral method remains robust. 
Keywords — Glucose control, integral-based parameter 
identification, model-based therapeutics, Intensive Care Unit 
I. INTRODUCTION  
Therapy guidance using physiological models is a 
growing trend in bio-engineering [1, 2]. Glucose control in 
the intensive care unit (ICU), has been dramatically 
improved by using a glucose-insulin model to optimize 
insulin doses and changes of nutrition [2-4, 9-11]. A 
glucose control protocol SPRINT (specialized reduced 
insulin nutrition table) has changed clinical practice in the 
Christchurch Intensive Care Unit [5]. The result is tight 
control of blood glucose with a 32% hospital mortality 
reduction. Parameter identification is an important part of 
the overall process, as the identified parameters affect the 
overall therapy prediction.  
An integral-based parameter identification method has 
been developed [6] and extended to other physiological 
systems that avoids the need for any forward simulations. It 
can thus dramatically reduce the computation required. 
These integral methods are therefore well suited to model-
based control applications requiring real-time parameter 
identification or large Monte Carlo analyses off-line. This 
paper investigates different computationally fast 
formulations that don’t require forward simulations. 
The glucose-insulin model and methods are tested using 
retrospective clinical data. Several practical issues that arise 
in clinical implementation are addressed, to highlight issues 
of performance and stability. 
Finally, a new model-based control method for metabolic 
control is presented, that combines a non-invasive 
continuous glucose sensor (CGMS) [7] with current 
standard glucometer sensors [8]. This method is shown to 
provide a potentially significant improvement in glucose 
control in simulation that warrants further clinical 
investigation in the future. 
II. METHODOLOGY 
A. Glucose-insulin model 
The glucose-insulin model is defined [6, 9-11]: 
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where G(t) is the plasma glucose concentration (mmol/L); 
GE the equilibrium level of plasma glucose concentration 
(mmol/L); Q(t) the interstitial insulin; I(t) the concentration 
of the plasma insulin above basal level (mU/L); P(t) the 
exogenous glucose infusion rate (mmol/(L min)); u(t) the 
insulin infusion rate (mU/min); V the assumed insulin 
distribution volume (L); n the delay in interstitial transfer of 
insulin (min-1); pG the fractional clearance of plasma 
glucose at basal insulin (min-1); SI the time-varying insulin 
sensitivity (L/mU min); k the parameter controlling the 
effective half life of insulin (min-1); and Gα  the Michaelis-
Menten parameter for glucose clearance saturation. For 
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more details on the construction and physiological 
interpretation of the model Equations (1)-(2) see [6, 9-11]. 
B. Parameter identification 
For the glucose-insulin Equations (1)-(2), a similar 
integral-based parameter identification method to [6] is 
applied. The parameters Gα , k, n and pG in Equations (1)-
(2) are held constant at the population values based on prior 
studies and sensitivity analysis [6]: 
 01.0,16.0,0099.0,
65
1
==== GG pnkα  (3) 
Similarly, the parameter GE is held at the mean glucose 
of each patient. The carbohydrate input, P(t) in Equations 
(1) and (2) is also held constant, but may change with 
respect to time for different patients. The exogenous insulin 
u(t)=uI is assumed to be a constant infusion over the hour. 
The parameter SI is insulin sensitivity and is assumed 
unknown.  
Integrating Equation (1) from 0 to t yields and choosing 
n values of time, ],60,0[,,,1 ∈= nttt …  ( ntt <<< "10 ), a 
set of n equations are formulated: 
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where ( ) / (1 )GQ t Q Q= + α . To avoid any error in G(0) 
potentially propagating through the equations, G0 = G(0) is 
assumed unknown and is identified along with SI. Equations 
(4) can be written as a matrix system:  
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where G is a continuous approximation to the measured 
glucose [6] and the integrals are evaluated by the trapezium 
rule. Equation (5) can be solved by linear least squares to 
determine SI as a constant over any period. Thus, IS  may 
be identified as piecewise constant. 
For glucose control in the Intensive Care Unit (ICU), 
Equation (1) is utilized over periods of 1 hour [9, 11] and 
glucose is measured on the hour. For two glucose 
measurements )0(0 GG =  and )60(60 GG = , the function 
G(t) in Equation (5) can be approximated by a straight line 
[6]. For a given infusion uI, nutritional input P(t) and 
glucose measurements G0 and G60, the solution to Equation 
(5) determines the required insulin sensitivity. However, 
note that a similar approach could be used if glucose is 
measured more frequently. 
A similar, potentially simpler, approach to the parameter 
identification of Equations (4)-(5) is to use the original 
differential Equations (1)-(2), rather than an integral 
formulation. For a given set of values, nttt ,,0 …= , n+1 
equations can be formulated: 
 ( ) ( ) ( ) ( ) , 0, ,i G i I i iG t Pp G t S Q t G t i n= − − + = …  (6) 
where t0=0. The analogous matrix system to Equation (5) is 
defined: 
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where )( itG are determined by standard finite differences. 
Equation (7) can be solved by linear least squares to 
determine SI. 
This method applies gradients which is similar in concept 
to typical gradient descent methods. The major difference is 
that no forward simulations are required so like the integral 
method [6] it is a computationally fast way of identifying 
large numbers of IS  or other time-varying parameters. 
C. Controlling Drug Delivery 
For the control of blood glucose G(t) in Equation (1), 
measurements are assumed to be taken every hour with a 
normally distributed absolute error of 7%, which is typical 
for a commercial glucometer [8]. Model-based control of 
glucose typically starts by taking two measurements G0 and 
G60 at the times 0 and 60 minutes and computing the insulin 
sensitivity SI from Equation (5). The goal is to determine the 
required insulin infusion u=uI in Equation (2) that will bring 
glucose down to a target value Gtarget in the next hour. This 
process is performed numerically at each intervention 
period. 
III. RESULTS AND DISCUSSION 
A. Glucose control in the Christchurch ICU 
The glucose control protocol SPRINT [3-5] is used 
extensively in the Christchurch ICU. One of the keys to the 
success of SPRINT is the significant testing of model-based 
glucose control algorithms on “virtual” patients prior to 
implementation. The major physiological variable that is 
used to represent a “virtual” patient profile is the time 
varying insulin sensitivity profile in Equation (1) that can be 
identified from retrospective data. 
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The insulin sensitivity profiles provide a means to 
simulate physiologically realistic time varying glucose 
response to different insulin and nutrition regimes. This 
approach thus provides a repeatable cohort for easy 
comparison of various protocols. It also gives insight into 
long term clinical performance, and, importantly, lets 
algorithms and methods be tested safely before clinical 
implementation. 
B. Parameter identification – Integral versus Derivative 
Several numerical studies have been done using data 
from the retrospective cohort of [6]. For brevity, the results 
are summarized: 
 
(1)  Patients with quite high average insulin infusion, have 
glucose response close to a straight line between hourly 
measurements. In this case both the integral and derivative 
methods perform similarly. 
 
(2) Clinically, periods where the glucose response is 
significantly different from a straight line can occur when 
there is an increase in feed from a period of low insulin 
infusion. During these periods the derivative method greatly 
underestimates the insulin sensitivity, and in some cases 
goes negative, even without measurement noise. The result 
of an underestimated SI value, is an overestimated infusion 
or bolus which can be dangerous as hyperglycemia may 
result. This scenario can happen reasonably frequently, so 
the method of choice is the integral method. 
C. Model-based glucose control 
To demonstrate the practical aspects of model-based 
glucose control, the integral method is applied to an insulin 
sensitivity profile from [6]. The patient is Patient 519, who 
was a male aged 69; type 2 diabetic; medical subgroup - 
General Surgical; APACHE II score - 29. The nutritional 
input was initially held constant at 0.049 mmol/(Lmin), GE 
was held constant at the mean measured glucose value of 
5.84 mmol/L and the maximum infusion allowed was 6 
units. 
Fig 1 (a) shows the result of simulated glucose control 
using the integral method for parameter identification and 
with 7% noise placed on the measurements. The mean 
glucose and standard deviation of 5.58 ± 1.03 mmol/L with 
67.57% of glucose values lying in the 4.0 to 6.1 mmol/L 
band. The reason for this decrease in performance is that 
there are significant periods in Figure 14 where the insulin 
has reached the maximum of 6 Units/hour so effectively no 
added, but necessary, control is being applied in these 
periods and insulin effect is saturated [1, 12]. 
 
 
 
 
 
 
 
 
 
 
 
            (a)     (b) 
Fig. 1 (a) Model-based glucose control with the time varying 
of Figure 12 and a fixed nutritional input given in Equation (22). 
(b) Model-based glucose control with the time varying SI 
and a simply varying nutritional input. 
The solution to this problem has been to vary the nutrition, 
as well as the insulin [10, 11]. A fully developed and 
validated method for modulating both the nutrition and 
insulin in a model-based glycemic control system is detailed 
in [11]. 
To demonstrate the essential concept the nutrition is 
dropped to 40% of the original value, whenever the insulin 
hits the upper limit of 6 units. This simple rule results in  
a significant improvement in glucose control as shown in 
Fig 1 (b). The mean glucose is 5.32 ± 0.67 mmol/L with 
76.14% of values lying between 4 and 6.1 mmol/L. 
D. Combining CGMS with glucocard measurements 
To demonstrate a new clinical application of the methods 
presented and to further investigate the comparison of the 
integral versus derivative approaches, a CGMS sensor is 
included in the model-based glucose control algorithm. The 
CGMS sensor measures glucose every 5 minutes with a 
measurement error that can be approximated by the 
formula: 
 (1 0.18 ) ,noise trueGG = + δ  ( 0, 1)μ σ= =  (8) 
where δ is the normal distribution. Equation (8) gives a 
mean absolute error of 14%, which is typical for CGMS 
sensors [7]. Blood glucose is still assumed to be measured 
hourly with a glucocard and 7% uniformly distributed noise 
in addition to the CGMS for comparison. To account for the 
extra noise in the CGMS and to give the greatest chance for 
an averaging effect on the errors, insulin sensitivity SI is 
fitted over the prior 1½ hours rather than 1 hour. The 
intervention period is also shortened to ½ hour to take 
advantage of the extra measurements from CGMS. The 1½ 
hour periods ensure that 2 glucocard measurements will 
always be available to fit SI when stepping along each 
interval of ½ hour. 
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A further change that is made is that 7% low frequency 
modelling error is added to the glucose measurements, as 
well as the normally distributed error in Equation (8). The 
final expression for noise is thus defined: 
 2(1 0.18 ) 1 0.07cos
82noise true
t GG πδ ⎛ ⎞⎛ ⎞= + − ⎜ ⎟⎜ ⎟⎝ ⎠⎝ ⎠
 (9) 
Equation (9) reflects the fact that a higher resolution in 
measurements, trades off with both a higher amount of 
sensor error and importantly, modelling error.  
Fig 2(a) shows the resulting glucose control for Patient 
519 using the same parameters as used for Fig 1. A 
significant improvement can be seen with a mean glucose of 
5.03 ± 0.42 mmol/L and 98.55% of glucose  values lying 
between 4 and 6.1 mmol/L.  
However, for the derivative method, even with 
smoothing to remove most of the local noise, a significantly 
worse result is seen in Fig 2(b). The mean glucose is 
5.5 ± 1.1 mmol/L with only 64.86% of glucose values lying 
between 4.0 and 6.1 mmol/L. Thus, the derivative method is 
unable to take advantage of the extra CGMS data, where the 
integral method gives significantly better outcomes on 
glucose control despite the larger noise distribution for these 
sensors. 
 
 
 
 
 
 
 
 
 
 
         (a)               (b) 
Fig. 2 (a) Model-based glucose control using the integral method 
with the combination of a CGMS sensor and glucocard. 
(b) Model-based glucose control using the derivative method 
and with a CGMS sensor and glucocard. 
IV. CONCLUSIONS  
The main results are summarized: 
 
• The integral formulation in parameter identification is 
very important for robust and reliable results, 
particularly with respect to modelling error which is 
always present in clinical applications. 
• The derivative method is very sensitive to modelling 
error and only works in situations where model 
response is close to a straight line.  
• The combination of the integral method and model-
based drug control is very effective for designing and 
testing new protocols.  
 
The integral method is thus an important research tool in the 
model-based therapeutics approach. For example the 
addition of simulated CGMS shows that a potentially 
significant clinical gain could be achieved with this 
continuous sensor. However, further investigation with real 
CGMS data is required to validate these results.  The 
derivative method, went unstable and failed to realize this 
possible clinical gain, further emphasizing the importance 
of integrals in the formulation. 
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